Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APRE logo APRE
Upturn stock ratingUpturn stock rating
APRE logo

Aprea Therapeutics Inc (APRE)

Upturn stock ratingUpturn stock rating
$1.51
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: APRE (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10.5

1 Year Target Price $10.5

Analysts Price Target For last 52 week
$10.5 Target price
52w Low $1.41
Current$1.51
52w High $5.01

Analysis of Past Performance

Type Stock
Historic Profit -40.93%
Avg. Invested days 39
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.99M USD
Price to earnings Ratio -
1Y Target Price 10.5
Price to earnings Ratio -
1Y Target Price 10.5
Volume (30-day avg) 3
Beta 1.58
52 Weeks Range 1.41 - 5.01
Updated Date 09/15/2025
52 Weeks Range 1.41 - 5.01
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2868.3%

Management Effectiveness

Return on Assets (TTM) -39.12%
Return on Equity (TTM) -67.54%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -7537997
Price to Sales(TTM) 10.69
Enterprise Value -7537997
Price to Sales(TTM) 10.69
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.35
Shares Outstanding 5825260
Shares Floating 4635801
Shares Outstanding 5825260
Shares Floating 4635801
Percent Insiders 11.3
Percent Institutions 31.2

ai summary icon Upturn AI SWOT

Aprea Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics. It was founded in 2003 and went public in 2019. Initially focused on small molecule therapies, it pivoted to oligonucleotide therapeutics.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on developing new therapies for cancer treatment. Their leading product is oligonucleotide therapies designed to target specific cancer-causing genes.

leadership logo Leadership and Structure

The company is led by a Board of Directors and an executive management team with experience in biotechnology and pharmaceuticals.

Top Products and Market Share

overview logo Key Offerings

  • ATR-008: Aprea's lead product candidate, an oligonucleotide therapeutic targeting ATR. It is in clinical development for different types of cancer. Market share data is not publicly available as it is still in clinical development. Competitors developing ATR inhibitors include Merck KGaA, Vertex Pharmaceuticals, and Bayer.

Market Dynamics

industry overview logo Industry Overview

The oncology drug development market is highly competitive and rapidly evolving, with significant investment in novel therapies.

Positioning

Aprea Therapeutics is positioned as a biotechnology company focused on innovative therapies. Its competitive advantage lies in its oligonucleotide technology.

Total Addressable Market (TAM)

The global cancer therapeutics market is estimated to be worth hundreds of billions of dollars. Aprea targets specific genetic mutations within that large TAM.

Upturn SWOT Analysis

Strengths

  • Novel oligonucleotide technology
  • Strong intellectual property position
  • Experienced management team
  • Clinical stage assets

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on clinical trial outcomes
  • Single lead product candidate
  • High cash burn rate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline to include other oligonucleotide therapies
  • Positive clinical trial results
  • FDA approval of ATR-008

Threats

  • Clinical trial failures
  • Competition from other cancer therapies
  • Regulatory hurdles
  • Patent challenges
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • VRTX
  • BAYRY

Competitive Landscape

Aprea faces strong competition from established pharmaceutical companies with greater resources. Its success depends on demonstrating the clinical efficacy of its therapies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is dependent on clinical trial progress and financing activities.

Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals.

Recent Initiatives: Aprea is focused on advancing ATR-008 through clinical trials.

Summary

Aprea Therapeutics is a high-risk, high-reward biotechnology company focused on developing innovative cancer therapies. Success hinges on positive clinical trial results and regulatory approval for their lead product candidate. The company's financial health and ability to secure partnerships will be crucial for long-term growth. Investors should be aware of the inherent risks involved in investing in clinical-stage biotechnology companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Website
  • Market Research Reports
  • Financial News Outlets

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investing in biotechnology companies involves significant risks, and investors should conduct their own due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aprea Therapeutics Inc

Exchange NASDAQ
Headquaters Doylestown, PA, United States
IPO Launch date 2019-10-03
Co-Founder, CEO, President & Director Dr. Oren Gilad Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.